CD8A and neoplasm: Taken together, these data extend our previous finding that GPI-0100 is able to significantly enhance the immunogenicity of TA-CIN including an E7-specific CD8+ T cell response and here show its potential for therapeutic activity against HPV16-transformed tumor in C57BL6 mice.